Myricx Bio

About Myricx Bio

Myricx Bio is a biotech company headquartered in London, focused on discovering and developing a novel class of payloads for antibody drug conjugates (ADCs) based on inhibitors of N-myristoyltransferases (NMT) for the treatment of cancer.

Products & Services

Antibody Drug Conjugates (ADCs):A proprietary pipeline of new generation ADCs targeting significant unmet needs in oncology, demonstrating excellent preclinical efficacy and safety across multiple solid tumor associated antigens and cancer cell types.

Specialties

Antibody Drug Conjugates (ADCs) N-myristoyltransferases (NMT) inhibition Oncology

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Series A T: - FT: Series A	A: 114000000 MR: - FA: £90m ($114m) FAN: 114000000	D: 2024-07-08 FD: 2024-07-08	7 investors

Series A Latest

2024-07-08

$114.0M

7 investors (Pro only)

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

R

Roberto Solari

Co-founder, founding CEO and Biology Consultant

E

Ed Tate

Professor

G

Grant Hawthorne

N

Nikki D'Arcy

PhD

J

Josephine Walton

A

Ateequllah Hayat

PhD

View 21 more team members with Pro

Unlock Full Team Directory

Recent News

Myricx Bio Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised